semaglutide nejm weight loss Tirzepatide vs for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% at 72 wks • Semaglutide: −13.7% • Greater waist reduction Oral Semaglutide 25 mg and

ARA 290 Peptide shows promising potential in autoimmune conditions, including increasing insulin sensitivity, relieving nerve pain, and addressing heart and cardiovascular diseases

Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, et al

No one was surprised when, with the expiry of the patent on diabetes drug sitagliptin in 2022, 30 branded generics hit chemist shops in India within a month

How many more have gone unnoticed or unreported

GLP-1 receptor activation improves B cell function and survival following induction of endoplasmic reticulum stress

Medical weight management is provided independently by Ellie Adams, FNP-BC, through her own independent medical practice